Status: Finalised
First registered on:
18/11/2013
Last updated on:
28/07/2016
1. Study identification
EU PAS Register NumberEUPAS5177
Official titlePOST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN SWEDEN
Study title acronym
Study typeObservational study
Brief description of the studyThis will be a descriptive study using retrospectively collected data from electronic health record
databases. The study will describe the utilization pattern of apixaban in Sweden (01 Jan 2012 through 31 Dec 2014).
Was this study requested by a regulator?Yes: Germany, United Kingdom
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupDivision of Clinical Pharmacology
Organisation/affiliationKarolinska Institutet
Details of (Primary) lead investigator
Title Dr
Last name Schachterle
First name Stephen
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
Sweden
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed16/09/201116/09/2011
Start date of data collection01/10/201405/11/2014
Start date of data analysis
Date of interim report, if expected
Date of final study report31/05/201620/05/2016
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesBristol-Myers Squibb, Pfizer100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Schachterle
First name Stephen
Address line 1219 East 42nd Street
Address line 2
Address line 3
CityNew York
Postcode10017
CountryUnited States
Phone number (incl. country code)1-212-7339192
Alternative phone number1-646-2705462
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Schachterle
First name Stephen
Address line 1219 East 42nd Street
Address line 2
Address line 3
CityNew York
Postcode10017
CountryUnited States
Phone number (incl. country code)1-212-7339192
Alternative phone number1-646-2705462
Fax number (incl. country code)
6. Study drug(s) information
Product NameEliquis
CountryUnited States
Substance INN(s)APIXABAN
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects17592
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
Swedish National Healthcare Registries, Sweden
Sources of data
Swedish National Healthcare Registries
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
The overall objective of this study is to describe the utilization patterns of apixaban in Sweden.
Are there primary outcomes?Yes
Off label use of apixaban.
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Descriptive analyses of the data will be conducted. The proportion
of patients receiving the drug for indications within and outside the approved label in each of the study years will be estimated and any trend over time will be described.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
